pbabe-hTERT+p53DD Citations (5)
Originally described in: A network of genetic events sufficient to convert normal human cells to a tumorigenic state.Kendall SD, Linardic CM, Adam SJ, Counter CM Cancer Res. 2005 Nov 1. 65(21):9824-8. PubMed Journal
Articles Citing pbabe-hTERT+p53DD
| Articles |
|---|
BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment.
Toledo CM, Herman JA, Olsen JB, Ding Y, Corrin P, Girard EJ, Olson JM, Emili A, DeLuca JG, Paddison PJ.
Dev Cell. 2014 Feb 10;28(3):282-94. doi: 10.1016/j.devcel.2013.12.014. Epub 2014 Jan 23.
PubMed
Associated Plasmids |
| A kinase-independent function of AKT promotes cancer cell survival. Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh WY, Yannuzzi N, Campos C, Mellinghoff IK. Elife. 2014 Dec 31;3. doi: 10.7554/eLife.03751. PubMed |
| MTA1 promotes viability and motility in nasopharyngeal carcinoma by modulating IQGAP1 expression. Lu B, Lian R, Wu Z, Miao W, Li X, Li J, Shi Y, Yu W. J Cell Biochem. 2018 May;119(5):3864-3872. doi: 10.1002/jcb.26494. Epub 2018 Jan 22. PubMed |
| Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. Ananthapadmanabhan V, Frost TC, Soroko KM, Knott A, Magliozzi BJ, Gokhale PC, Tirunagaru VG, Doebele RC, DeCaprio JA. JCI Insight. 2022 Jul 8;7(13). pii: 160513. doi: 10.1172/jci.insight.160513. PubMed |
| Combined transgene immortalized urothelial cells capable of reprogramming and hepatic differentiation. Weiand M, Ballmaier P, Niemietz C, Schmidt H, Zibert A. Biochem Biophys Rep. 2022 Jul 16;31:101308. doi: 10.1016/j.bbrep.2022.101308. eCollection 2022 Sep. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.